Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Don’t Miss

7 Aug 2023

News You Might Have Missed: Aug 7th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Finance

4 Aug 2023

MindMed Reports Second Quarter 2023 Financial Results and Highlights

MindMed released its Q3 financial results. Highlights include enrolment in Phase 2b LSD trial, top-line results by end-of-year, and $116 million in cash....

By Microdose NewsDesk

Industry

3 Aug 2023

Psyence Announces SEC Registration For NASDAQ (by SPAC Merger)

Psyence announces a SPAC merger and filing with the SEC for eventual NASDAQ trading....

By Microdose NewsDesk

Breaking News, Finance

1 Aug 2023

Raising Capital: Cybin Announces Public Offering

Cybin has announced a public offering for gross proceeds of US$8,250,000....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

28 Jul 2023

House Approves Psychedelics Research Amendments in Major Spending Bill

A bi-partisan amendment to promote research into psychedelics has passed a vote in the U.S. House of Representatives....

By Microdose NewsDesk

Industry

26 Jul 2023

EXCLUSIVE: Interview with Terran Biosciences founder Sam Clark

See Microdose's exclusive Q&A with Terran’s founder and CEO to learn more about the company and their recent discoveries....

By Microdose NewsDesk

Don’t Miss

25 Jul 2023

News You Might Have Missed: July 25th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Industry

24 Jul 2023

Cybin Announces Phase 2 Dosing Completion of CYB003 Trial (Cohort 5)

Cybin announces Phase 2 cohort 5 dosing completion of CYB003 in Major Depressive Disorder...

By Microdose NewsDesk

Law & Politics

24 Jul 2023

Minneapolis Mayor Signs Order Making Psychedelics ‘Lowest Law Enforcement Priority’

The mayor of Minneapolis signed an executive order making the criminalization of psychedelics the city’s lowest law enforcement priority....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.